Monday, 1 June 2020

Worldwide Cerebral Palsy Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2023

Market Scenario
Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral palsy can develop from several factors such as lack of oxygen to the brain, genetic conditions, brain infections, brain hemorrhage, chemical or substance abuse during pregnancy, injury to the head, and severe jaundice.
The global cerebral palsy market is driving owing to the growing prevalence of cerebral palsy coupled with increasing awareness about the condition. Moreover, the growing adoptions of medications for controlling the symptoms of the cerebral palsy are anticipated to propel the market growth. Additionally, increasing expenditure for the healthcare sector in developed economies and increasing insurance coverage contribute to the growth of the market.
Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.
Regional Summary
The Americas is expected to dominate the global cerebral palsy market during the forecast period owing to the well-established healthcare sector, growing awareness about CP, and the rising prevalence of cerebral palsy in the region. The European market is expected to be the second-largest market due to the growing healthcare expenditure and increasing prevalence of cerebral palsy. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the developing healthcare infrastructure, and favorable government initiatives for the healthcare sector. The Middle East & Africa is likely to account for the least cerebral palsy market share over global market owing to the lack of economic development, especially in the African region.
Key players
Some of the prominent players in the global cerebral palsy market are Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd.
Segmentation
The global cerebral palsy market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.
The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.
Posted by at No comments:

Cardiac Monitoring and Cardiac Rhythm Management Device Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

Global Cardiac Monitoring and Cardiac Rhythm Management Device Market, by Cardiac Device (Pacemaker and Others), by Cardiac Monitoring (Electrocardiogram), by CRM (Defibrillators and Others), by End-User (Hospitals and Others)–Global Forecast Till 2023
Market Scenario
Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also to growth in the market. The global cardiac monitoring and cardiac rhythm management device market is segmented into types of cardiac devices, types of cardiac monitoring devices, types of cardiac rhythm management devices, and end-users. Further, the types of cardiac devices are segmented into pacemaker, biventricular pacemaker, implantable cardioverter defibrillator, and implantable cardiac loop recorder. Based on the types of cardiac monitoring devices the market is further segmented into electrocardiogram (ECG), Holter monitor, event monitor, implantable loop recorder, and cardiac output monitoring devices. Electrocardiogram (ECG) is further sub-segmented into telelectro-cardiogram, wireless ECG, and lead ECG test. Based on types of cardiac rhythm management devices, the market is segmented into defibrillators, pacemakers, and cardiac resynchronization therapy devices. Defibrillations are further sub-segmented into implantable defibrillators and external defibrillators. Based on end-user the market is segmented into hospitals, ambulatory surgical centers, and others.
Global cardiac monitoring and cardiac rhythm management device market size is expected to grow during the forecast period (2018 to 2023) at a CAGR ~4%.
Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the cardiac monitoring and cardiac rhythm management device market. Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. The increasing demand for minimally invasive surgeries drives the growth of this market. However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market.
However, the high cost of these devices in developing nations, preference of drugs over devices in the cardiac treatment, and limited insurance coverage options are some of the factors which are hampering the growth of the market.
Key Players
Some of the key players in the global cardiac monitoring and cardiac rhythm management device market are Abiomed, Berlin Hearth, Brotionik SE and Co. KG, Boston Scientific Corporation, Cardiac Science Corporation, General Electric(GE), Hill Rom Services Inc, Jarvik Hearth. Inc, Koninklijke Philips N.V, LivaNova plc, Medtronic plc, Nihon Kohden Corporation, ReliantHeart Inc, Schiller, and Abbott.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The cardiac monitoring and cardiac rhythm management device market in the Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European cardiac monitoring and cardiac rhythm management device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cardiac monitoring and cardiac rhythm management device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiac monitoring device market in the Middle East and Africa has been segmented into the Middle East and Africa.
The European market is expected to be the second-largest cardiac monitoring device market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of surgeries due to the changing lifestyle is contributing to the growth of the market in this region. Asia-Pacific is expected to be the fastest-growing cardiac monitoring device market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving strong competition in the global cardiac monitoring device market by producing cost-effective products that are high in demand in local as well as global markets. The market in the Middle East and Africa is expected to account for the smallest share in the global cardiac monitoring device market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
In terms of market value, North America will dominate the global cardiac monitoring and cardiac rhythm management device market during the forecast period. The increasing investment by North America in cardiac devices over the last few years has led to the growth of the market in this region. Increasing number of cardiac patients, better healthcare infrastructure, and advanced technology in cardiac monitoring equipment have boosted the cardiac monitoring and cardiac rhythm management device market in North America.
Posted by at No comments:

Global Bone Implant Market Positive Growth And Forecasts By 2023

Market Scenario:
Bone implants are used to heal bone fractures or as fillers and scaffolds to facilitate the bone formation. Bone implants are surgically placed into the body and designed to restore the function by replacing or reinforcing a damaged structure. The rapid growth in aged population, increasing number of orthopedic surgeries, and rising occurrences of sports-related injuries are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by top players such as new product launches are contributing to the growth of the market. For instance, in May 2018, NN Inc. acquired Paragon Medical for USD 375 million. Paragon Medical is a medical device manufacturer which focuses on orthopedics, case and tray, and implant and instrument markets.  The acquisition supports NNs Inc.’s strategy to grow its life science revenue and positions NN Inc. as one of the ten largest contract manufacturers in orthopedics.
The rising cost of orthopedic surgeries, the high price of bone implant products, corrosion and instability of bioimplants, and stringent government policies may hinder the growth of the market during the assessment period.
The Global Bone Implant Market is expected to grow during the forecast period (2018–2023) at a CAGR ~6.8%.
Regional Market Summary
The Americas is likely to dominate the global bone implant market. The rising occurrence of osteoarthritis and osteoporosis in the aging population, increase in the number of surgical procedures, the presence of a well-established healthcare system, growing prevalence of sports injuries, and adoption of highly advanced technology are contributing to the growth of the market. According to the Annual Report of the American Joint Replacement Registry (AJRR), 860,080 hip and knee replacement procedures from 4,755 surgeons at 654 institutions were conducted in 2017.
Asia-Pacific is expected to be the fastest-growing bone implant market during the forecast period owing to the increasing prevalence of medical tourism, orthopedic diseases along with bone-related issues, and rising investments in healthcare and expansions by market players in the region. Asia-Pacific is anticipated to show significant growth from 2018 to 2023
The European market is expected to be the second-largest bone implant market. The market growth in this region can be attributed to the rising prevalence of orthopedic diseases. Moreover, the increasing demand for orthopedic implants and spinal treatment devices during the forecast period are contributing to the growth of the market in this region. Major players are adapting inorganic growth policies to expand their portfolio. For instance, Stryker Corporation, a major player in the orthopedic implants market acquired Vexim for USD 215 million in 2017. Vexim offers spine related products, which helped Stryker Corporation to capture the new segment.
The market in the Middle East and Africa is expected to account for the smallest share of the global bone implant market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Key Players
  • Depuy Synthes Inc. (Johnson & Johnson),
  • Globus Medical, Inc.,
  • NuVasive, Inc.,
  • Smith & Nephew plc. ,
  • Stryker Corporation,
  • Zimmer Biomet Holdings, Inc.,
  • Integra LifeSciences Holdings Corporation,
  • Medtronic, plc,
  • The Orthopedic Implant Company,
  • Wright Medical Group N.V.,
  • Aesculap Implant Systems,
  • BioTek Instruments, Inc.,
  • Conmed Corporation,
  • Arthrocare Corporation.
Segmentation
The global bone implant market has been segmented on the basis of biomaterial, product, application, device, and end-user.
On the basis of biomaterial, the market has been classified as metals, ceramics, and polymers. The metal segment has been further divided into titanium, stainless steel, cobalt chromium alloy, gold alloys, and Tantalum. The ceramics segment has been further divided into alumina, hydroxyapatite, beta-tricalcium, phosphate, carbon, bioglass, zirconia, and zirconia-toughened alumina. The polymers segment has been classified into polymethylmethacrylate, polytetrafluoroethylene, polyethylene, polysulfone, polyurethane, and polyether ether ketone.
The market, by products, is divided into orthopedic screws, orthopedic plates, interlocking nails (rods), and others. The market, by application, has been classified into hip orthopedic implants, knee orthopedic implants, spine orthopedic implants, dental orthopedic implants, and others.
The market, by device, is divided into external fixators and internal fixators.
The market, by end-user, has been segmented into orthopedic clinics, hospitals, and others.
Posted by at No comments:

Sacroiliitis Market Expects An Extensive Growth In Roi Till 2023

Market Scenario
The global sacroiliitis market is expected to witness growth during the forecast period. Sacroiliitis is a medical condition where there is inflammation in one or both sacroiliac joints situated in the pelvis and lower back. The function of a sacroiliac joint is to bear the weight of the upper body while standing, walking, and others. The condition can be diagnosed by imaging techniques. Sacroiliitis is caused due to traumatic injury, arthritis, pregnancy, infection, spondylitis, and others. The increasing prevalence of arthritis is the key factor for the market growth. According to the Centers for Disease Control and Prevention (2013to 2015), 22.7% Americans of the total population had arthritis, annually. Thus, such a high prevalence of arthritis and increasing government funding for the healthcare sector enhance the growth of this market.
However, factors such as expensive diagnostic tests and the high cost of surgical procedures are expected to restrict the market growth during the forecast period.
Segmentation
The global sacroiliitis market is segmented on the basis of diagnosis, treatment, and end-user. The sacroiliitis market, by diagnosis, is sub-segmented into imaging tests and anesthetic injections. The imaging tests category includes x-ray, MRI, and CT scan. On the basis of treatment, the market is categorized into medications, joint injections, radiofrequency denervation, electrical stimulation, joint fusion, facet block, chiropractic manipulation, and physical therapy. On the basis of end-user, the market is segmented into hospitals and clinics, pharmacies, and diagnostic centers.
On the basis of region, the global sacroiliitis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key players
Some of the key players in the global sacroiliitis market are Medacta International, SI-BONE, Globus Medical, Zyga Technology, Nutech Medical, CoorsTek Medical LLC, Aspen Medical Products, Medtronic, and others.
The sacroiliitis market is dominated by North America owing to the high prevalence of arthritis and high healthcare investments within this region. According to the Centers for Disease Control and Prevention by 2040, 78.4 million will have doctor-diagnosed arthritis.
The rising adoption of technologically advanced systems for early diagnosis of diseases also drives the market growth in this region.
It is estimated that Europe stood second in the global sacroiliitis market. The increasing prevalence of lower back disorders and the availability of minimally invasive surgical procedures for sacroiliitis drive the market growth in this region. According to The European (2015), sacroiliac joint was the main reason for chronic low back pain in Europe.
Asia-Pacific was projected to be the fastest growing region for the global sacroiliitis market. Key factors such as the growing patient pool, the high prevalence of chronic diseases, developing healthcare infrastructure, and increasing research and development activities in the biotechnology sector influence the market in this region. The presence of major market players such as China, India, and Japan drives the market growth.
The Middle East and Africa holds the least share of the global sacroiliitis market due to the presence of stringent government policies and poor economies. However, growing awareness among the population, rising government initiatives to improve the healthcare sector, and high investments by private market players in this region can boost the market growth. 
Posted by at No comments:

Thursday, 28 May 2020

World Immunofluorescence Assay Market Top Key Players Shares, Revenue, Analysis And Forecasts To 2023

Market Scenario
The growing prevalence of chronic and infectious diseases increase in research and development activities, growing government investments for R&D activities, increased need for rapid and sensitive diagnostics, and adoption of technologically advanced systems are the key factors for the market to grow. However, factors such as, expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
The Global Immunofluorescence Assays Market Size is expected to reach an approximate CAGR of 5.8% during the forecast period.
According to National Institutes of Health (2012), autoimmune diseases are most prevalent among other diseases, and 23.5 million people in America suffer from autoimmune diseases, whereas 9 million people have cancer. Furthermore, according to Alzheimer's Association in 2018, 5.7 million Americans are affected by Alzheimer’s disease.  Thus, such high incidence of autoimmune and neurological diseases and increasing government funding enhances the growth in this market. Also, growing demand for rapid and precise measurement of biomolecules, increased use of Immunofluorescence Assay for diagnostic and research purposes, increased R&D activities and advanced technology are the key factors for the market to grow.
However, factors such as expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
Key Players
Some of the key players for the global Immunofluorescence Assay market are Abcam plc, Thermo Fisher Scientific, BioLegend, Inc., Enzo Life Sciences, Inc., Sino Biological Inc.,BioTek Instruments,Inc., Bio-Rad Laboratories, Inc., Zyagen, Cell Signaling Technology, Inc., PerkinElmer Inc. Becton Dickinson and Company , Merck , Agilent Technologies , TCS Biosciences Ltd, Maxvision Biosciences Inc. and Others.
Segmentation
The global immunofluorescence assay market is segmented on the basis of technique, product type, application and end user. The immunofluorescence assay market, by technique is sub segmented into primary (direct) immunofluorescence assays, secondary (indirect) immunofluorescence assays, and micro immunofluorescence. Secondary (indirect) immunofluorescence assays category includes salt split technique, antigenic mapping method and double staining method. On the basis of product type, the market is categorized into antibodies, kits and reagents, instruments, labelling dyes and species type. Instruments is further sub segmented into microscopes and imaging analysis systems. The application segment includes clinical research, clinical diagnostics, research & development. Clinical diagnostics segment is categorized into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, neurological diseases. On the basis of end-user, the market is segmented into biotechnology companies, hospitals & research institutes, contract research organizations and diagnostic centers.
Regional Market Summary
The Immunofluorescence Assay market is dominated by North America owing to the high prevalence of chronic diseases and high R&D investments within this region stimulate market growth. According to the U.S. Investments in Medical and Health Research and Development in 2016, the United States invested total $171.8 billion in medical and health R&D and the investment increased by 20.6% from 2013 to 2016. Also, the rising adoption of technologically advanced systems for early diagnosis of diseases drives the market growth in this region.
It is estimated that Europe stood second in the global Immunofluorescence Assay market. Rising prevalence of chronic diseases such as cancer is driving the growth of this market in Europe. According to the Eurostat in 2014, 272 thousand people deaths were due to lung cancer. Thus, increasing prevalence of cancer in Europe drives the market growth. Furthermore, rapidly growing biotechnology sector in Europe is expected to boost the market in this region.
Asia Pacific was projected to be the fastest growing region for the global Immunofluorescence Assay market. Key factors such as growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure and increasing research & development activities in biotechnology sector influences the market in this region. Also, the presence of major market players China, India, and Japan drive the market growth.
The Middle East and Africa holds the least share in the global Immunofluorescence Assay market due to the presence of stringent government policies and poor economies. However, growing awareness among the population and high investments by private market players in this region can boost the market growth. 
Posted by at No comments:

Global Overactive Bladder Treatment Market 2019 To 2023 Professional Overview, Detail Analysis, Growth And Top Key Players Demand

Market Scenario:
Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market analysis during the assessment period.
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market growth is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
Company Profiles    
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc. 
  • Mylan N.V. 
  • Endo International Plc 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi S. A.
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc.
  • Others
Segmentation
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.

Posted by at No comments:

Digital Wound Measurement Devices Market Expects An Extensive Growth In Roi Till 2023

Market Highlights
The global digital wound measurement devices market is expected to witness a positive growth during the forecast period.
The growing prevalence of chronic wounds, increasing prevalence of diabetes, increase in technological advancements in medical devices, growing government support for healthcare developments, rising geriatric population, increased need for rapid diagnostics, adoption of advanced digital tools, and advent of telehealth for wound care are the key factors for the digital wound measurement devices market to grow. However, factors such as, the inability of the device to provide additional information about wounds such as moistness or exudation and high costs of the digital devices are expected to restrict the market growth during the forecast period.
Segmentation
The global digital wound measurement devices market is segmented on the basis of wound type, product, and end-user. The digital wound measurement devices market, by wound type is sub-segmented into diabetic ulcer, chronic wounds, burns, incisional, and traumatic. The product segment is sub-segmented into contact wound measuring devices and non-contact wound measuring devices.
On the basis of end-user, the market is segmented into hospitals, clinics, and ambulatory surgical centers
Regional Analysis
The Americas dominated the global market for digital wound measurement devices market in 2017. This can be attributed to the increasing prevalence of chronic wounds, rising R&D activities in medical devices, and rapid adoption of technologically advanced medical devices within the region. According to the Intermountain Healthcare (2017), 6.5 million people in the Americas suffer from chronic wounds and the US spends approximately 25 billion annually on wound care.
Europe (UK, Germany, and France) is the second largest market owing to rapidly growing incidences of wounds. According to the Health Awareness report 2016, the National Health Service (NHS) treated approximately 2.2 million wounds annually and 730000 leg ulcers. Such a high prevalence of wounds in this region influences the market growth in this region.
Asia-Pacific is expected to witness the fastest growth for the global digital wound measurement devices market owing to large diabetic patient population, rapidly growing economies such as China and India, rising medical tourism in this region, rapid digitalization in this region, and increase in research and development activities. The American Diabetes Association projected that the Western Pacific region is expected to have 201.8 million diabetic population by 2035. Such conditions provide favorable backgrounds for the market to grow.
The Middle East and Africa accounts for the least share due to stringent government policies and poor economies.
Key Players
Some of the key players for the global digital wound measurement devices market are WoundRight Technologies, Tissue Analytics, Parable Health, ARANZ Medical Limited, eKare, Inc., KCI, an Acelity Company, WoundMatrix, Inc., WoundZoom Inc., Kent Imaging Inc., WoundRight Technologies, LLC, WoundVision, LLC, Hitachi Healthcare Americas, and Smith & Nephew plc.
Posted by at No comments:
Subscribe to: Posts (Atom)